Work

1234eTiP OVATION-3: A randomized phase III trial evaluating the safety and efficacy of intraperitoneal IL-12 gene therapy administered in combination with standard neoadjuvant and adjuvant chemotherapy (N/ACT) in newly-diagnosed patients with advanced epithelial ovarian cancer (EOC)

Year: 2025

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.1867

Authors: P.H. Thaker, C.J. Darus, M. Indermaur, M. Bergman, C.A. Leath, D.V. Faller, L. Musso, S.R. Lindborg, K. Anwer, K. Longobardi, M. Quintana, G. Paulon, A.A. Jazaeri, W.H. Bradley

Institutions: Washington University in St. Louis, University of Alabama at Birmingham, University of Louisville, Berry Consultants, LLC (United States), The University of Texas MD Anderson Cancer Center, Froedtert Hospital, Medical College of Wisconsin

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415940382

FWCI:

Cites:

Cited by:

Related to: